Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer-Reference-Cited by-同舟云学术

Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer

Published:2019-08 Issue: Volume:29 Page:118-122
ISSN:2352-5789
Container-title:Gynecologic Oncology Reports
language:en
Short-container-title:Gynecologic Oncology Reports

Author:

Lee Elizabeth K.,Tan-Wasielewski Zhenying,Matulonis Ursula A.,Birrer Michael J.,Wright Alexi A.,Horowitz Neil,Konstantinopoulos Panagiotis A.,Curtis Jennifer,Liu Joyce F.

Funder

AstraZeneca

Pfizer

Merck

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference15 articles.

1. Dual targeting of protein degradation pathways with the selective HDAC6 inhibitor ACY-1215 and bortezomib is synergistic in lymphoma;Amengual;Clin Cancer Res.,2015

2. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors;Bali;J. Biol. Chem.,2005

3. ARID1A-mutated ovarian cancers depend on HDAC6 activity;Bitler;Nat. Cell Biol.,2017